Ultimate
Predictability

genOway offers preclinical models and solutions to bio-pharmaceutical and academic researchers for ultimate predictability.
We will be attending AACR 2025 in Chicago! Book a 1:1 with our scientific experts here
Learn more
Watch how the humanized genO-hFcγR mouse better predicts antibody efficacy and safety
Learn more
Caedo Oncology used our genO-hCD47/hSIRPα to test the safety of their monoclonal antibody, Magrolimab
Learn more

Ensuring the ultimate predictability of your research

At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Our team of experts brings together decades of experience in designing genetically modified models and a profound understanding of biological physiology to provide unmatched preclinical solutions.

Our collaborative approach, rooted in a deep understanding of your specific needs and complemented by our expertise, strives to define the best solution to predict the success of your research. Join us on a journey of scientific advancement for the benefit of human health.

  • 28
    countries worldwide
  • 380
    academic institutions
  • 13
    EU projects
  • 170
    Life Sciences companies
  • 17
    of the Top 20 pharma

Catalog models

Explore our comprehensive catalog of preclinical models, featuring genetically modified mice, rats, and cell lines. All our models were designed and validated with the highest standards of excellence to ensure the ultimate predictability of your research.

Learn more

Customized models

Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. With an in-depth understanding of your needs, our team of scientific experts, committed to your side, will accompany you throughout this journey.

Learn more
Our latest resources and publications
Posters
Scientific Articles
Commentaries
Case studies
(Seismic) Discovery and characterization of a novel engineered Fc-fused IgE cleaving enzyme for treatment of IgE mediated diseases

Allergic and atopic diseases with genO-hIgE/hFcεRI

Apr 2025
(Evotec) Modeling Inflammatory Bowel Disease in mice with “Humanized” immune system

Inflammatory bowel disease with genO-BRGSF-HIS

Mar 2025
(AstraZeneca) AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens

T-cell engager assessment with Pan hCD3

Nov 2024
Show all posters
Reactivation of CTLA4-expressing T cells Accelerates Resolution of Lung Fibrosis in a Humanized Mouse Model

J Clin Invest

2025
Evolutionary fingerprints of epithelial-to-mesenchymal transition

Nature

2025
An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor

Gynecol Oncol

2025
Show all scientific articles
Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

10 min read
-
Mar 2025
A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

7 min read
-
Oct 2024
New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

5 min read
-
Oct 2024
Show all commentaries
No items found.
Show all case studies